(Q36718474)

15 August 2017

1 reference

title

Emerging options for treatment of invasive, multidrug-resistant Staphylococcus aureus infections (English)

1 reference

15 August 2017

main subject

multiple drug resistance

1 reference

based on heuristic

inferred from title

Staphylococcus aureus

1 reference

Richard H Drew

1

1 reference

15 August 2017

language of work or name

English

0 references

publication date

1 February 2007

1 reference

15 August 2017

1 reference

15 August 2017

volume

27

1 reference

15 August 2017

issue

2

1 reference

15 August 2017

page(s)

227-249

1 reference

Community-acquired methicillin-resistant Staphylococcus aureus: a meta-analysis of prevalence and risk factors

15 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.2.227

Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.2.227

The impact of methicillin resistance in Staphylococcus aureus bacteremia on patient outcomes: mortality, length of stay, and hospital charges

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.2.227

Clinical and economic impact of methicillin resistance in patients with Staphylococcus aureus bacteremia

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.2.227

Adverse clinical and economic outcomes attributable to methicillin resistance among patients with Staphylococcus aureus surgical site infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.2.227

Methicillin-resistant Staphylococcus aureus prolongs intensive care unit stay in ventilator-associated pneumonia, despite initially appropriate antibiotic therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.2.227

21 January 2018

Vancomycin: a history

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.2.227

The role of vancomycin in the treatment paradigm

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.2.227

Adaptation of methicillin-resistant Staphylococcus aureus in the face of vancomycin therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.2.227

Antimicrobial susceptibility of Staphylococcus aureus and Staphylococcus epidermidis biofilms isolated from infected total hip arthroplasty cases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.2.227

Pharmacodynamics of vancomycin and other antimicrobials in patients with Staphylococcus aureus lower respiratory tract infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.2.227

The pharmacokinetic and pharmacodynamic properties of vancomycin

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.2.227

Potential impact of vancomycin pulmonary distribution on treatment outcomes in patients with methicillin-resistant Staphylococcus aureus pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.2.227

Trends in antimicrobial resistance in health care-associated pathogens and effect on treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.2.227

Decreased susceptibility to glycopeptides in methicillin-resistant Staphylococcus aureus: a 20 year study in a large French teaching hospital, 1983-2002.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.2.227

Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.2.227

Emergence of vancomycin resistance in Staphylococcus aureus. Glycopeptide-Intermediate Staphylococcus aureus Working Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.2.227

The development of vancomycin resistance in a patient with methicillin-resistant Staphylococcus aureus infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.2.227

Whole genome sequencing of meticillin-resistant Staphylococcus aureus

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.2.227

The progressive intercontinental spread of methicillin-resistant Staphylococcus aureus

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.2.227

Staphylococcus aureus with Heterogeneous Resistance to Vancomycin: Epidemiology, Clinical Significance, and Critical Assessment of Diagnostic Methods

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.2.227

Clinical features associated with bacteremia due to heterogeneous vancomycin-intermediate Staphylococcus aureus

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.2.227

Comparison of community- and health care-associated methicillin-resistant Staphylococcus aureus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.2.227

The changing epidemiology of Staphylococcus aureus?

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.2.227

Epidemiology and clonality of community-acquired methicillin-resistant Staphylococcus aureus in Minnesota, 1996-1998.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.2.227

High prevalence of methicillin-resistant Staphylococcus aureus in emergency department skin and soft tissue infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.2.227

Activity of daptomycin against susceptible and multidrug-resistant Gram-positive pathogens collected in the SECURE study (Europe) during 2000-2001.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.2.227

Baseline Study To Determine In Vitro Activities of Daptomycin against Gram-Positive Pathogens Isolated in the United States in 2000-2001

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.2.227

Clinical and molecular epidemiology of community-acquired methicillin-resistant Staphylococcus aureus infections among children with risk factors for health care-associated infection: 2001-2003.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.2.227

Epidemiological and microbiological characterization of infections caused by Staphylococcus aureus with reduced susceptibility to vancomycin, United States, 1997-2001.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.2.227

Vancomycin-intermediate Staphylococcus aureus in a home health-care patient

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.2.227

Laboratory reporting of Staphylococcus aureus with reduced susceptibility to vancomycin in United States Department of Veterans Affairs facilities

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.2.227

In vitro activity of 21 antimicrobials against vancomycin-resistant Staphylococcus aureus (VRSA) and heteroVRSA (hVRSA).

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.2.227

Trimethoprim-sulfamethoxazole compared with vancomycin for the treatment of Staphylococcus aureus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.2.227

Staphylococcal skin infections in children: rational drug therapy recommendations

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.2.227

Epidemiology and treatment of community-associated methicillin-resistant Staphylococcus aureus in children

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.2.227

Practice guidelines for the diagnosis and management of skin and soft-tissue infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.2.227

Activity of and resistance to moxifloxacin in Staphylococcus aureus

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.2.227

Activity of AZD2563, a novel oxazolidinone, against Staphylococcus aureus strains with reduced susceptibility to vancomycin or linezolid

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.2.227

Characterization of a strain of community-associated methicillin-resistant Staphylococcus aureus widely disseminated in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.2.227

Methicillin-resistant Staphylococcus aureus disease in three communities

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.2.227

Pseudomonas aeruginosa, Staphylococcus aureus, and fluoroquinolone use.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.2.227

Risk factors for acquisition of methicillin-resistant Staphylococcus aureus (MRSA) by patients with cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.2.227

Evaluation of an intervention designed to decrease the rate of nosocomial methicillin-resistant Staphylococcus aureus infection by encouraging decreased fluoroquinolone use.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.2.227

Guidelines for the prophylaxis and treatment of methicillin-resistant Staphylococcus aureus (MRSA) infections in the UK.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.2.227

Investigation of erythromycin and tetracycline resistance genes in methicillin-resistant staphylococci

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.2.227

Clinical and laboratory features of community-associated methicillin-resistant Staphylococcus aureus: is it really new?

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.2.227

Contrasting pediatric and adult methicillin-resistant Staphylococcus aureus isolates

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.2.227

Spectrum and potency evaluation of a new oxazolidinone, linezolid: report from the SENTRY Antimicrobial Surveillance Program, 1998-2000.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.2.227

Fifteen-year study of the changing epidemiology of methicillin-resistant Staphylococcus aureus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.2.227

Clindamycin treatment of invasive infections caused by community-acquired, methicillin-resistant and methicillin-susceptible Staphylococcus aureus in children

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.2.227

Bacterial resistance to macrolide, lincosamide, and streptogramin antibiotics by target modification

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.2.227

Practical disk diffusion method for detection of inducible clindamycin resistance in Staphylococcus aureus and coagulase-negative staphylococci

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.2.227

Community-onset methicillin-resistant Staphylococcus aureus bacteremia in Northern Australia

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.2.227

Prospective comparison of risk factors and demographic and clinical characteristics of community-acquired, methicillin-resistant versus methicillin-susceptible Staphylococcus aureus infection in children

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.2.227

Failure of Clindamycin Treatment of Methicillin-Resistant Staphylococcus aureus Expressing Inducible Clindamycin Resistance In Vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.2.227

Inducible clindamycin resistance and molecular epidemiologic trends of pediatric community-acquired methicillin-resistant Staphylococcus aureus in Dallas, Texas

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.2.227

Clindamycin in the treatment of soft tissue infections: a review of 15 019 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.2.227

Clindamycin treatment of methicillin-resistant Staphylococcus aureus infections in children

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.2.227

Pathogen of occurrence and susceptibility patterns associated with pneumonia in hospitalized patients in North America: results of the SENTRY Antimicrobial Surveillance Study (2000)

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.2.227

In vitro susceptibility patterns of methicillin-resistant and-susceptible Staphylococcus auerues strains in a population of parenteral drug abusers from 1972 to 1981.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.2.227

Infective endocarditis: diagnosis, antimicrobial therapy, and management of complications: a statement for healthcare professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Y

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.2.227

Role of rifampin for treatment of orthopedic implant-related staphylococcal infections: a randomized controlled trial. Foreign-Body Infection (FBI) Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.2.227

Combination antimicrobial therapy for Staphylococcus aureus endocarditis in patients addicted to parenteral drugs and in nonaddicts: A prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.2.227

Combination antibiotic therapy for infective endocarditis

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.2.227

Guidelines for the antibiotic treatment of endocarditis in adults: report of the Working Party of the British Society for Antimicrobial Chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.2.227

Use of long-acting tetracyclines for methicillin-resistant Staphylococcus aureus infections: case series and review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.2.227

In vitro activity of tigecycline against 6792 Gram-negative and Gram-positive clinical isolates from the global Tigecycline Evaluation and Surveillance Trial (TEST Program, 2004).

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.2.227

Successful outpatient treatment of sinusitis exacerbations caused by community-acquired methicillin-resistant Staphylococcus aureus

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.2.227

Quinupristin-dalfopristin and linezolid: evidence and opinion

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.2.227

In vitro activities of quinupristin-dalfopristin and cefepime, alone and in combination with various antimicrobials, against multidrug-resistant staphylococci and enterococci in an in vitro pharmacodynamic model

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.2.227

A multicenter evaluation of linezolid antimicrobial activity in North America

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.2.227

Trends in linezolid susceptibility patterns in 2002: report from the worldwide Zyvox Annual Appraisal of Potency and Spectrum Program

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.2.227

Oxazolidinone susceptibility patterns in 2004: report from the Zyvox Annual Appraisal of Potency and Spectrum (ZAAPS) Program assessing isolates from 16 nations

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.2.227

Antibacterial susceptibility of a vancomycin-resistant Staphylococcus aureus strain isolated at the Hershey Medical Center

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.2.227

Linezolid resistance in clinical isolates of Staphylococcus aureus

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.2.227

Linezolid resistance in a clinical isolate of Staphylococcus aureus

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.2.227

Linezolid resistance in Staphylococcus aureus: characterization and stability of resistant phenotype

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.2.227

Emergence of linezolid-resistant Staphylococcus aureus during treatment of pulmonary infection in a patient with cystic fibrosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.2.227

Linezolid (PNU-100766) versus vancomycin in the treatment of hospitalized patients with nosocomial pneumonia: a randomized, double-blind, multicenter study

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.2.227

Continuation of a randomized, double-blind, multicenter study of linezolid versus vancomycin in the treatment of patients with nosocomial pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.2.227

Linezolid versus vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.2.227

Linezolid versus vancomycin in treatment of complicated skin and soft tissue infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.2.227

Linezolid eradicates MRSA better than vancomycin from surgical-site infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.2.227

Efficacy and safety of linezolid compared with vancomycin in a randomized, double-blind study of febrile neutropenic patients with cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.2.227

Clinical and economic outcomes of oral linezolid versus intravenous vancomycin in the treatment of MRSA-complicated, lower-extremity skin and soft-tissue infections caused by methicillin-resistant Staphylococcus aureus

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.2.227

Linezolid versus vancomycin for Staphylococcus aureus bacteraemia: pooled analysis of randomized studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.2.227

Linezolid: the first oxazolidinone antimicrobial

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.2.227

Linezolid: a review of its use in the management of serious gram-positive infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.2.227

Thrombocytopenia associated with linezolid therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.2.227

Worldwide assessment of linezolid's clinical safety and tolerability: comparator-controlled phase III studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.2.227

Safety and tolerability of linezolid

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.2.227

High frequency of linezolid-associated thrombocytopenia and anemia among patients with end-stage renal disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.2.227

Good clinical outcomes but high rates of adverse reactions during linezolid therapy for serious infections: a proposed protocol for monitoring therapy in complex patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.2.227

Possibly linezolid-induced peripheral and central neurotoxicity: report of four cases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.2.227

Linezolid-associated toxic optic neuropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.2.227

Linezolid-induced optic neuropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.2.227

Linezolid-induced lactic acidosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.2.227

Linezolid and Serotonin Toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.2.227

Serotonin toxicity associated with concomitant use of linezolid

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.2.227

Serotonin toxicity associated with the use of linezolid: a review of postmarketing data

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.2.227

Comparison of length of hospital stay for patients with known or suspected methicillin-resistant Staphylococcus species infections treated with linezolid or vancomycin: a randomized, multicenter trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.2.227

Guidelines for the Management of Adults with Hospital-acquired, Ventilator-associated, and Healthcare-associated Pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.2.227

A consensus statement on empiric therapy for suspected gram-positive infections in surgical patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.2.227

Linezolid for the treatment of multidrug-resistant, gram-positive infections: experience from a compassionate-use program

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.2.227

Linezolid for the treatment of patients with endocarditis: a systematic review of the published evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.2.227

Linezolid in the treatment of osteomyelitis: results of compassionate use experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.2.227

Bactericidal activity of quinupristin-dalfopristin against Staphylococcus aureus: clindamycin susceptibility as a surrogate indicator

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.2.227

Treatment of experimental endocarditis due to erythromycin-susceptible or -resistant methicillin-resistant Staphylococcus aureus with RP 59500

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.2.227

Bactericidal activity of quinupristin-dalfopristin against strains of Staphylococcus aureus with the MLS(B) phenotype of resistance according to the erm gene type.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.2.227

Cross-resistance analyses and molecular typing of Staphylococcus aureus and Streptococcus spp. isolates resistant to quinupristin/dalfopristin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.2.227

Susceptibility of gram-positive cocci from 25 UK hospitals to antimicrobial agents including linezolid. The Linezolid Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.2.227

Antimicrobial activity of quinupristin-dalfopristin (RP 59500, Synercid) tested against over 28,000 recent clinical isolates from 200 medical centers in the United States and Canada.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.2.227

Treatment of methicillin-resistant staphylococcus aureus infections with quinupristin-dalfopristin in patients intolerant of or failing prior therapy. For the Synercid Emergency-Use Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.2.227

Quinupristin/dalfopristin: a therapeutic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.2.227

Daptomycin: a lipopeptide antibiotic for the treatment of serious Gram-positive infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.2.227

Correlation of daptomycin bactericidal activity and membrane depolarization in Staphylococcus aureus

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.2.227

In vitro and in vivo activities of tigecycline (GAR-936), daptomycin, and comparative antimicrobial agents against glycopeptide-intermediate Staphylococcus aureus and other resistant gram-positive pathogens

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.2.227

Comparative In vitro activities of daptomycin and vancomycin against resistant gram-positive pathogens

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.2.227

Daptomycin Dose-Effect Relationship against Resistant Gram-Positive Organisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.2.227

Pharmacodynamic profile of daptomycin against Enterococcus species and methicillin-resistant Staphylococcus aureus in a murine thigh infection model

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.2.227

In vitro activities of daptomycin, vancomycin, linezolid, and quinupristin-dalfopristin against Staphylococci and Enterococci, including vancomycin- intermediate and -resistant strains

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.2.227

In vitro activities of daptomycin against 2,789 clinical isolates from 11 North American medical centers

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.2.227

Daptomycin susceptibility tests: interpretive criteria, quality control, and effect of calcium on in vitro tests.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.2.227

In vitro bactericidal activity of daptomycin against staphylococci

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.2.227

The in vitro activity of daptomycin against 514 Gram-positive aerobic clinical isolates

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.2.227

Activity of daptomycin against Gram-positive pathogens: a comparison with other agents and the determination of a tentative breakpoint

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.2.227

Daptomycin in vitro susceptibility in European Gram-positive clinical isolates

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.2.227

Activity of daptomycin against multi-resistant Gram-positive bacteria including enterococci and Staphylococcus aureus resistant to linezolid

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.2.227

The in vitro activity of daptomycin against Staphylococcus aureus and Enterococcus species

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.2.227

Induction of daptomycin heterogeneous susceptibility in Staphylococcus aureus by exposure to vancomycin

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.2.227

Correlation between Reduced Daptomycin Susceptibility and Vancomycin Resistance in Vancomycin-Intermediate Staphylococcus aureus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.2.227

Bactericidal activities of daptomycin, quinupristin-dalfopristin, and linezolid against vancomycin-resistant Staphylococcus aureus in an in vitro pharmacodynamic model with simulated endocardial vegetations

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.2.227

Methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococci: prevalence and predictors of colonization in patients presenting to the emergency department from nursing homes

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.2.227

Daptomycin bactericidal activity and correlation between disk and broth microdilution method results in testing of Staphylococcus aureus strains with decreased susceptibility to vancomycin

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.2.227

Daptomycin-resistant, methicillin-resistant Staphylococcus aureus bacteremia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.2.227

Treatment failure resulting from resistance of Staphylococcus aureus to daptomycin

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.2.227

Emergence of a clinical daptomycin-resistant Staphylococcus aureus isolate during treatment of methicillin-resistant Staphylococcus aureus bacteremia and osteomyelitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.2.227

Diminished susceptibility to daptomycin accompanied by clinical failure in a patient with methicillin-resistant Staphylococcus aureus bacteremia

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.2.227

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.2.227

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.2.227

The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.2.227

Daptomycin for treating infected diabetic foot ulcers: evidence from a randomized, controlled trial comparing daptomycin with vancomycin or semi-synthetic penicillins for complicated skin and skin-structure infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.2.227

Use of daptomycin to treat drug-resistant Gram-positive bone and joint infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.2.227

Inhibition of daptomycin by pulmonary surfactant: in vitro modeling and clinical impact

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.2.227

Development of daptomycin for gram-positive infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.2.227

Once-daily dosing in dogs optimizes daptomycin safety

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.2.227

The glycylcyclines: a comparative review with the tetracyclines

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.2.227

Diagnostic PCR analysis of the occurrence of methicillin and tetracycline resistance genes among Staphylococcus aureus isolates from phase 3 clinical trials of tigecycline for complicated skin and skin structure infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.2.227

In vitro activity of tigecycline (GAR-936), a novel glycylcycline, against vancomycin-resistant enterococci and staphylococci with diminished susceptibility to glycopeptides

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.2.227

Antimicrobial activity of tigecycline tested against nosocomial bacterial pathogens from patients hospitalized in the intensive care unit

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.2.227

Potency and spectrum of tigecycline tested against an international collection of bacterial pathogens associated with skin and soft tissue infections (2000-2004).

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.2.227

Antimicrobial activity of tigecycline tested against organisms causing community-acquired respiratory tract infection and nosocomial pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.2.227

Tigecycline activity tested against 26,474 bloodstream infection isolates: a collection from 6 continents

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.2.227

In vitro activity of tigecycline against 3989 Gram-negative and Gram-positive clinical isolates from the United States Tigecycline Evaluation and Surveillance Trial (TEST Program; 2004).

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.2.227

Antimicrobial activity of tigecycline (GAR-936) tested against 3498 recent isolates of Staphylococcus aureus recovered from nosocomial and community-acquired infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.2.227

Antimicrobial activity of tigecycline (GAR-936) against Enterococcus faecium and Staphylococcus aureus used alone and in combination

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.2.227

In vivo pharmacodynamic activities of two glycylcyclines (GAR-936 and WAY 152,288) against various gram-positive and gram-negative bacteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.2.227

Pharmacokinetics, pharmacodynamics, safety and tolerability of tigecycline

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.2.227

Tigecycline for the treatment of infections due to resistant Gram-positive organisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.2.227

The efficacy and safety of tigecycline for the treatment of complicated intra-abdominal infections: analysis of pooled clinical trial data

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.2.227

The efficacy and safety of tigecycline in the treatment of skin and skin-structure infections: results of 2 double-blind phase 3 comparison studies with vancomycin-aztreonam

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.2.227

Pharmacokinetics of Tigecycline after Single and Multiple Doses in Healthy Subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.2.227

Activities of LY333328 and vancomycin administered alone or in combination with gentamicin against three strains of vancomycin-intermediate Staphylococcus aureus in an in vitro pharmacodynamic infection model

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.2.227

In vitro killing of community-associated methicillin-resistant Staphylococcus aureus with drug combinations

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.2.227

Combination of quinupristin-dalfopristin (Synercid) and rifampin is highly synergistic in experimental Staphylococcus aureus joint prosthesis infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.2.227

Slow response to vancomycin or vancomycin plus rifampin in methicillin-resistant Staphylococcus aureus endocarditis

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.2.227

Synercid plus vancomycin for the treatment of severe methicillin-resistant Staphylococcus aureus and coagulase-negative staphylococci infections: evaluation of 5 cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.2.227

Combining quinupristin/dalfopristin with other agents for resistant infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.2.227

Combination of quinupristin/dalfopristin and glycopeptide in severe methicillin-resistant staphylococcal infections failing previous glycopeptide regimens

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.2.227

AZD2563, a new oxazolidinone: bactericidal activity and synergy studies combined with gentamicin or vancomycin against staphylococci and streptococcal strains

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.2.227

Vancomycin and oxacillin synergy for methicillin-resistant staphylococci

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.2.227

Pharmacodynamics of cefepime alone and in combination with various antimicrobials against methicillin-resistant Staphylococcus aureus in an in vitro pharmacodynamic infection model

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.2.227

Synergy of daptomycin with oxacillin and other beta-lactams against methicillin-resistant Staphylococcus aureus

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.2.227

Combination of minocycline and rifampicin against methicillin- and gentamicin-resistant Staphylococcus aureus

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.2.227

In vitro activity of minocycline and rifampin against staphylococci

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.2.227

In vitro activities of LY333328 and comparative agents against nosocomial gram-positive pathogens collected in a 1997 global surveillance study

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.2.227

Pharmacodynamics of Oritavancin (LY333328) in a Neutropenic-Mouse Thigh Model of Staphylococcus aureus Infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.2.227

Oritavancin and tigecycline: investigational antimicrobials for multidrug-resistant bacteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.2.227

Origin, structure, and activity in vitro and in vivo of dalbavancin

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.2.227

Dalbavancin: an investigational glycopeptide

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.2.227

Activity of dalbavancin against staphylococci and streptococci, assessed by BSAC and NCCLS agar dilution methods

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.2.227

Antistaphylococcal activity of dalbavancin, an experimental glycopeptide

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.2.227

Antimicrobial activity of dalbavancin tested against Gram-positive clinical isolates from Latin American medical centres

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.2.227

Worldwide assessment of dalbavancin activity and spectrum against over 6,000 clinical isolates

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.2.227

Spectrum and potency of dalbavancin tested against 3322 Gram-positive cocci isolated in the United States Surveillance Program (2004).

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.2.227

In vitro activities of dalbavancin and 12 other agents against 329 aerobic and anaerobic gram-positive isolates recovered from diabetic foot infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.2.227

Activities of dalbavancin in vitro and in a rabbit model of experimental endocarditis due to Staphylococcus aureus with or without reduced susceptibility to vancomycin and teicoplanin

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.2.227

Once-weekly dalbavancin versus standard-of-care antimicrobial regimens for treatment of skin and soft-tissue infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.2.227

Randomized, double-blind comparison of once-weekly dalbavancin versus twice-daily linezolid therapy for the treatment of complicated skin and skin structure infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.2.227

Dalbavancin compared with vancomycin for prevention of Staphylococcus aureus colonization of devices in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.2.227

Efficacy and safety of weekly dalbavancin therapy for catheter-related bloodstream infection caused by gram-positive pathogens

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.2.227

Telavancin, a multifunctional lipoglycopeptide, disrupts both cell wall synthesis and cell membrane integrity in methicillin-resistant Staphylococcus aureus

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.2.227

In vitro activity of TD-6424 against Staphylococcus aureus

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.2.227

Pharmacokinetics, serum inhibitory and bactericidal activity, and safety of telavancin in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.2.227

Telavancin versus standard therapy for treatment of complicated skin and skin structure infections caused by gram-positive bacteria: FAST 2 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.2.227

Evaluation of ceftobiprole in a rabbit model of aortic valve endocarditis due to methicillin-resistant and vancomycin-intermediate Staphylococcus aureus

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.2.227

Iclaprim, a novel diaminopyrimidine with potent activity on trimethoprim sensitive and resistant bacteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.2.227

In vitro activity of faropenem against 5460 clinical bacterial isolates from Europe

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.2.227

Comparative in vitro activity of faropenem against staphylococci

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.2.227

Open-label, dose escalation study of the safety and pharmacokinetic profile of tefibazumab in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.2.227

Phase II, randomized, double-blind, multicenter study comparing the safety and pharmacokinetics of tefibazumab to placebo for treatment of Staphylococcus aureus bacteremia

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.2.227

Use of a Staphylococcus aureus conjugate vaccine in patients receiving hemodialysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.2.227

21 January 2018

Identifiers

DOI

10.1592/PHCO.27.2.227

1 reference

15 August 2017

1 reference